From: Checkpoint inhibitor therapy in preclinical sepsis models: a systematic review and meta-analysis
Study (author, year) | Exp ID | Checkpoint inhibitor regimen* | Bacterial challenge** | Additional non-bacterial challenge | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Challenge regimen | Antibiotic regimen | Challenge regimen | Antimicrobial regimen | ||||||||||||||
Target | Time@ | Dose | Route | Type | Site | Dose | Type | Time@ | Type | Time@ | Site | Dose | Type | Time@ | Route | ||
Seo, 2008 | 1 | PD-L1 | D-1 | 200 μg | IP | L. mono | IV | 30000 CFU | NR | NR | NA | ||||||
Zhang, 2010 | 1 | PD-L1 | D-1 | 50 μg | IP | CLP | IP | NA | NR | NR | NA | ||||||
2 | PD-L1 | D0& | 50 μg | IP | CLP | IP | NA | NR | NR | NA | |||||||
Kobayashi, 2013 | 1 | BTLA# | D0^^ | 400 μg | IP | LPS | IP | 750 μg | NA | NA | NA | ||||||
Cheng, 2016 | 1 | BTLA# | D-1 | 25 μg/g | IV | CLP | IP | NA | NR | NR | Hem | D-1 | NA | ||||
D0 | 25 μg/g | IP | |||||||||||||||
Deng, 2018 | 1 | PD-L1 | D0,+1,+2,+3@@ | 20 mg/kg | NR | CLP | IP | NA | NR | NR | NA | ||||||
2 | PD-L1 | D0,+1,+2,+3@@ | 20 mg/kg | NR | CLP | IP | NA | NR | NR | NA | |||||||
Patil, 2018 | 1 | PD-L1 | D-1 | 50 μg | IP | P. aer | ID | 1x106 CFU | NR | NR | Burn | D-4 | Skin | NA | |||
2 | PD-L1 | D-1 | 200 μg | IP | S. aur | IV | 1x108 CFU | NR | NR | Burn | D-4 | Skin | NA | ||||
Brahmamdam, 2010 | 1 | PD-1 | D+1, +2 | 200 μg | IV | CLP | IP | NA | NR | NR | NA | ||||||
Inoue, 2011 | 1 | CTLA-4 | D0,+1@@, && | 50 μg | IP | CLP | IP | NA | Imi | D0 | NA | ||||||
2 | CTLA-4 | D0, +1 | 200 μg | IP | CLP | IP | NA | Imi | D0 | NA | |||||||
3 | CTLA-4 | D0,+1, +2@@ | 50 μg | IP | CLP | IP | NA | Imi | D0 | NA | |||||||
4 | CTLA-4 | D+6,+9,+11 | 33 μg | IP | CLP | IP | NA | Imi | D0 | C. alb | D+4 | IV | UC | NR | NR | NR | |
Chang, 2013 | 1 | PD-1 | D+5,+8,+11 | 200 μg | IP | CLP | IP | NA | Imi | D+1 | C. alb | D+3 | IV | UC | Fluc | D+9-12 | IP |
2 | PD-L1 | D+5,+8,+11 | 200 μg | IP | CLP | IP | NA | Imi | D+1 | C. alb | D+3 | IV | UC | Fluc | D+9-12 | IP | |
3 | CTLA-4 | D+4 | 100 μg | IP | CLP | IP | NA | Imi | D+1 | C. alb | D+3 | IV | UC | Fluc | D+9-12 | IP | |
Shindo, 2015 | 1 | PD-1 | D+4,+8 | 200 μg | IP | CLP | IP | NA | Imi | D0 | C. alb | D+3 | IV | UC | Fluc | D+5,+6 | IP |
Shindo, 2017 | 1 | PD-L1^ | D+5 to D+13 (TID) | 3 mg/kg | SC | CLP | IP | NA | Imi | D0 | C. alb | D+3 | IV | UC | NR | NR | NR |